Tvardi Therapeutics, Inc. (TVRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.70M
Last updated: Nov 17, 2026 at 4:10 PM ET
Tvardi Therapeutics, Inc. (TVRD) Statistics
Tvardi Therapeutics (TVRD) has a market cap of $14.70M. Its share count is up 34.94% from a year earlier. It holds $22.27M more cash than debt, 151.53% of its market cap.
Total Valuation
| Market Cap | $14.70M |
|---|---|
| Latest price (Nov 17, 2026) | $1.01 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.8x |
|---|---|
| P/TBV Ratio | 0.8x |
Price Statistics
The stock is down 74.94% over 52 weeks and trades 15.83% below its 50-day average.
| Beta (1Y) | 1.81 |
|---|---|
| 52-Week Change | -74.94% |
| 1-Month Change | +4.12% |
| 3-Month Change | -46.28% |
| 6-Month Change | -72.78% |
| 5-Year Change | -99.87% |
| 10-Year Change | -99.69% |
| Total Return (1Y) | -74.94% |
| Total Return (3Y CAGR) | -70.56% |
| Total Return (5Y CAGR) | -71.34% |
| Return vs SPY (1Y) | -87.04% |
| Max Drawdown (1Y) | -84.14% |
| Max Drawdown (3Y) | -98.24% |
| Sharpe Ratio (1Y) | -1.16 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $1.20 |
| 200-Day Average | $2.56 |
| 52-Week Range | $0.77 to $5.69 |
| RSI (14 Days) | 45.5 |
| Average Volume (20 Days) | 365.95K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.86x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.86x |
|---|---|
| Quick Ratio | 2.86x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -202.72% and return on assets is -133.14% over the last 12 months.
| Return on Equity (ROE) | -202.72% |
|---|---|
| Return on Assets (ROA) | -133.14% |
| Return on Capital Employed (ROCE) | -191.27% |
| ROA (5Y Average) | -63.44% |
Scores
TVRD has an Altman Z-Score of -10.26, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.26 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was -$2.57M over the last 12 months.
| Revenue | -$2.57M |
|---|---|
| Gross Profit | -$2.57M |
| Operating Income | -$29.56M |
| Pretax Income | -$38.49M |
| Net Income | -$31.33M |
| EBITDA | -$29.55M |
| EBIT | -$29.56M |
| Reported EPS (TTM) | -$2.68 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 65.70% of the $23.53M in total assets.
| Cash and Equivalents | $22.27M |
|---|---|
| Total Debt | $0 |
| Net Cash | $22.27M |
| Net Cash Per Share | $1.76 |
| Working Capital | $15.05M |
| Shareholder Equity | $15.46M |
| Book Value Per Share | $1.22 |
| Tangible Book Value | $15.18M |
| Tangible Book Per Share | $1.20 |
| Total Assets | $23.53M |
| Total Liabilities | $8.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$27.15M |
|---|---|
| FCF Per Share | -$2.04 |
| Depreciation and Amortization | $178.00K |
Trailing 12 months through Sep 30, 2026.
Stock Splits
The last split was a 1-for-3 reverse split on Apr 16, 2025.
| Last Split Date | Apr 16, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:3 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TVRD
What is TVRD's market cap?
Tvardi Therapeutics has a market cap of $14.70M.
How many shares of TVRD are outstanding?
Tvardi Therapeutics has 12.65M shares outstanding. The count is up 34.94% from a year earlier.
Does TVRD pay a dividend?
No. Tvardi Therapeutics does not pay a dividend.
How much debt does TVRD have?
Tvardi Therapeutics has $0 of total debt and $22.27M of cash and equivalents, a net cash position of $22.27M.
TVRD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors